Skip to Main Content
Skip Nav Destination

Cancer is a crucial reason for death in almost all emerging nations. Huge anti-cancer agents were recognized are still requiring progress in enduring rates and eminence for cancer-affected life. PIM1 belongs to the serine/threonine kinase family, and has been recognized as a distinct target in oncogenesis. The role of PIM 1 is denotable in survival, cellular senescence, cell cycle regulation, drug resistance, and apoptosis and it appears as a probable biomarker in many human malignancies. Today numerous stimulating inhibitors for PIM1 are expanded and few were withdrawn from clinical trials of phase1 and 2, due to the absence of toxicity and bioavailability. Henceforth the determination of the current work is to invent more effective and to minimize lethal compounds. A sequence of novel 2-oxindoles with dithiocarbamates were outlined as PIM1 inhibitors. All the compounds molecular properties were predicted using softwares like Swiss ADME, Molinspiration, Molsoft and pkCSM that are essential for drug candidate. Additionally, in order to perceive the binding affinity of designed molecules with PIM1 kinase protein and to explain their anticancer activity, molecular docking study was accomplished. Outcomes revealed that all the designed molecules satisfied the drug likeliness and bioavailability conditions with low toxicity. All twenty molecules were docked into the PIM1 kinase active site using AutoDock Vina. The results declared that compounds 16 and 18 exhibit better binding energy values, which are commensurable with formerly reported compounds AZ1208 and SGI1776. This study supports the scholars to get a finer drug for cancer treatment.

This content is only available via PDF.
You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal